BR112022019632A2 - Marcadores peptídicos e parceiros de ligação - Google Patents

Marcadores peptídicos e parceiros de ligação

Info

Publication number
BR112022019632A2
BR112022019632A2 BR112022019632A BR112022019632A BR112022019632A2 BR 112022019632 A2 BR112022019632 A2 BR 112022019632A2 BR 112022019632 A BR112022019632 A BR 112022019632A BR 112022019632 A BR112022019632 A BR 112022019632A BR 112022019632 A2 BR112022019632 A2 BR 112022019632A2
Authority
BR
Brazil
Prior art keywords
binding partners
peptide
peptide markers
peptide tags
pairs
Prior art date
Application number
BR112022019632A
Other languages
English (en)
Portuguese (pt)
Inventor
Frederik Sander Bertelsen Adam
Elyette Fougeroux Cyrielle
Susan Thrane
Original Assignee
Adaptvac Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adaptvac Aps filed Critical Adaptvac Aps
Publication of BR112022019632A2 publication Critical patent/BR112022019632A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
BR112022019632A 2020-05-07 2021-05-07 Marcadores peptídicos e parceiros de ligação BR112022019632A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20173377 2020-05-07
PCT/EP2021/062113 WO2021224451A1 (en) 2020-05-07 2021-05-07 Peptide tags and binding partners

Publications (1)

Publication Number Publication Date
BR112022019632A2 true BR112022019632A2 (pt) 2023-10-03

Family

ID=70613720

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019632A BR112022019632A2 (pt) 2020-05-07 2021-05-07 Marcadores peptídicos e parceiros de ligação

Country Status (11)

Country Link
US (1) US20230321260A1 (enExample)
EP (1) EP4146675A1 (enExample)
JP (2) JP7843245B2 (enExample)
KR (1) KR20230006473A (enExample)
CN (1) CN115698045A (enExample)
AU (1) AU2021268757B2 (enExample)
BR (1) BR112022019632A2 (enExample)
CA (1) CA3177709A1 (enExample)
IL (1) IL297111A (enExample)
MX (1) MX2022013938A (enExample)
WO (1) WO2021224451A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
WO2022229817A1 (en) * 2021-04-28 2022-11-03 Bavarian Nordic A/S Vaccines comprising virus-like particles displaying sars-cov-2 antigens and methods of use
US20240240203A1 (en) 2021-05-04 2024-07-18 SpyBiotech Limited Adenoviral vectors and vaccines thereof
WO2024068265A2 (en) 2022-09-30 2024-04-04 Bavarian Nordic A/S Virus-like particles displaying sars-cov-2 antigens as booster vaccines and uses thereof
CN116165377A (zh) * 2023-04-21 2023-05-26 常州伯仪生物科技有限公司 一种通过竞争elisa法进行标签蛋白定量的方法
WO2025097030A1 (en) * 2023-11-02 2025-05-08 Oregon State University Virus-like particles displaying neisseria gonorrhoeae antigens and use thereof for immunization against gonorrhea
GB202317925D0 (en) 2023-11-23 2024-01-10 Spybiotech Ltd Vaccines
CN117723749B (zh) * 2024-02-07 2024-06-04 南昌大学 基于分子粘合剂的动态光散射免疫传感检测方法
WO2026039325A2 (en) 2024-08-12 2026-02-19 Regeneron Pharmaceuticals, Inc. Modified mtm1 genes and uses thereof
WO2026119880A1 (en) * 2024-12-02 2026-06-11 Adaptvac Aps Vaccine for inducing antibodies to inhibit thymic stromal lymphopoietin
WO2026119878A1 (en) * 2024-12-02 2026-06-11 Adaptvac Aps Vaccine for inducing antibodies to inhibit native interleukin-11 signaling

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201002362D0 (en) 2010-02-11 2010-03-31 Isis Innovation Peptide tag systems that spontaneously form an irreversible link to protein partners via isopeptide bonds
CA2964119C (en) * 2014-11-03 2022-10-18 Merck Patent Gmbh Soluble intein fusion proteins and methods for purifying biomolecules
AU2016207099C1 (en) 2015-01-15 2021-02-04 University Of Copenhagen Virus-like particle with efficient epitope display
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
US11807671B2 (en) * 2016-11-16 2023-11-07 Auckland Uniservices Limited Methods for protein ligation and uses thereof
CN111073925B (zh) * 2018-10-19 2022-04-26 北京大学 一种基于无序蛋白偶联酶的高效多肽-多肽偶联系统和方法

Also Published As

Publication number Publication date
EP4146675A1 (en) 2023-03-15
KR20230006473A (ko) 2023-01-10
AU2021268757A1 (en) 2022-12-08
AU2021268757B2 (en) 2026-07-09
CN115698045A (zh) 2023-02-03
CA3177709A1 (en) 2021-11-11
MX2022013938A (es) 2022-11-30
JP2026048917A (ja) 2026-03-17
WO2021224451A1 (en) 2021-11-11
JP7843245B2 (ja) 2026-04-09
JP2023525752A (ja) 2023-06-19
IL297111A (en) 2022-12-01
US20230321260A1 (en) 2023-10-12
WO2021224451A9 (en) 2022-05-27

Similar Documents

Publication Publication Date Title
MX2022013938A (es) Etiquetas peptidicas y parejas de union.
CL2021003373A1 (es) Nuevos inhibidores de egfr
MX2020001080A (es) Anticuerpos con dominios funcionales en la region del codo entre el dominio variable y constante.
BR112022006977A2 (pt) Aminas bicíclicas como inibidores de cdk2
BR112022005995A2 (pt) Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas
CO2018006590A2 (es) Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1
CY1121891T1 (el) Τροποποιημενα με γενετικη μηχανικη πολυπεπτιδια της λυασης φαινυλαλανινης-αμμωνιας
EA201990785A1 (ru) Циклические динуклеотидные соединения
BR112018005928A2 (pt) composição ácida compreendendo uma ficocianina
BR112013003388A2 (pt) sal de besilato de um inibidor de btk
BR112018077188A2 (pt) frutose-6-fosfato-3-epimerase termoestável inovadora e um método para produzir alulose com o uso da mesma
BR112016022841A2 (pt) cadeia j modificada
BR112017019453A2 (pt) compostos e composições de alfa-cinamida como inibidores de hdac8
BR112017015627A2 (pt) Compostos de piperidina ureia substituída com 4- metilsulfonila para o tratamento de cardiomiopatia dilatada (dcm)
MX2020007531A (es) Aminopirrolotriazinas como inhibidores de cinasa.
MX2023008631A (es) Montajes de muelle helicoidal abierto.
BR112018007517A2 (pt) métodos para tratar esclerose múltipla usando compostos de pirimidina e piridina com atividade inibidora de btk
BR112018068103A2 (pt) anticorpos gitr, métodos e usos
MX379400B (es) Combinaciones novedosas de un antagonista de h3 y un inhibidor de recaptacion de noradrenalina y sus usos terapéuticos.
MX2023010076A (es) Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas.
EP3987514C0 (en) SCENE-BASED AUDIO DATA CORRELATION FOR PSYCHOACOUSTIC AUDIO CODING
EA201591421A1 (ru) Препараты полипептида фактора ix
MX2017012924A (es) Metodos para seleccionar inhibidores selectivos de fosfatasa e inhibidores no selectivos de fosfatasa.
BR112018003714A8 (pt) Composições de ácido de peso aumentado que compreendem aminoácidos
CL2019003003A1 (es) Un método mejorado para la producción de nivel alto de crm.